We develop content for the successful reimbursement and prescription of drugs and devices.

 

We facilitate strategic development decisions in market access, in ways such as:

  • analysing possible pricing scenarios
  • proposing pricing and price negotiation strategies
  • recommending value dossier content, and incorporating an HTA perspective
  • probing intangible value
  • economic evaluation
  • Validating expectations on Return on Investment: informing about potential risks and mitigating threats
  • Developing phase projects:
    • Definition of most relevant outcomes
    • Research & economic evaluation trials
    • Facilitating appropriate development of PoC and Research Trials: Sites, KOL.

We support health start-ups

Early stage

Drugs in the graveyard increase costs

This week we learned that Merck & Co. was ending the Phase III APECS study of Verubecestat (formerly known as MK-8931) for the treatment of prodromal Alzheimer Disease. Yet another drug in AD graveyard!!

read more